Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 96% Improvement Relative Risk Mortality (b) 95% Hospitalization 88% Hospitalization (b) 89% c19early.com/pl Hammond et al. NCT04960202 Paxlovid RCT EARLY TREATMENT Favors paxlovid Favors control
Hammond, 2,085 patient paxlovid early treatment RCT: 96% lower mortality [p=0.0005] and 88% lower hospitalization [p<0.0001] https://c19p.org/hammond
copied to clipboard
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond et al., New England Journal of Medicine, doi:10.1056/NEJMoa2118542
16 Feb 2022    Source   PDF   Share   Tweet
EPIC-HR RCT, 1,039 higher risk patients treated with paxlovid (PF-07321332 + ritonavir) and 1,046 control patients, showing significantly lower mortality and hospitalization with treatment. NCT04960202.
risk of death, 96.0% lower, RR 0.04, p < 0.001, treatment 0 of 1,039 (0.0%), control 12 of 1,046 (1.1%), NNT 87, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 5 days.
risk of death, 94.8% lower, RR 0.05, p = 0.002, treatment 0 of 697 (0.0%), control 9 of 682 (1.3%), NNT 76, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), within 3 days.
risk of hospitalization, 87.6% lower, RR 0.12, p < 0.001, treatment 8 of 1,039 (0.8%), control 65 of 1,046 (6.2%), NNT 18, within 5 days.
risk of hospitalization, 88.9% lower, RR 0.11, p < 0.001, treatment 5 of 697 (0.7%), control 44 of 682 (6.5%), NNT 17, within 3 days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hammond et al., 2/16/2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, multiple regions, peer-reviewed, 12 authors, average treatment delay 2.93 days, trial NCT04960202.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit